Kite gets US FDA nod for Yescarta to treat relapsed or refractory follicular lymphoma
Yescarta is the first CAR T-Cell therapy approved for indolent follicular lymphoma
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
follicular lymphoma
Rhizen Pharma’s partnered asset Umbralisib gets US FDA accelerated nod for relapsed or…
Umbralisib is a novel, next generation, oral, once daily, inhibitor of phosphoinositide 3 kinase (PI3K) delta and casein kinase 1…